💊 Препараты А-Я 🧬 Мишени 🛠 Инструменты 📚 Руководства
Все препараты Классы препаратов Терапевтические области Побочные Эффекты
Руководства Глоссарий Хронология
Сравнения Путешествия препаратов Группы лекарственных средств
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Tolcapone

CHEMBL1324 Phase 4 Одобрено Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
273.2 g/mol
LogP
3.3
Phase
4

This medication is used as an add-on treatment to levodopa/carbidopa therapy in Parkinson's disease patients who are experiencing fluctuations in symptom control ("wearing off" episodes). It works by blocking an enzyme called COMT, which breaks down levodopa, allowing more of it to reach the brain. Due to the risk of serious liver damage, it requires regular liver function monitoring and is only used when other options have not worked.

Молекулярная масса

273,2400 g/mol

LogP

3,30

TPSA

103,00 Ų

Правило пяти Липинского

Соответствует

Терапевтические области

Parkinson's Disease Schizophrenia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Структура

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
Cc1ccc(C(=O)c2cc(O)c(O)c([N+](=O)[O-])c2)cc1

                

                

                
                

                    
InChI

                    
InChI=1S/C14H11NO5/c1-8-2-4-9(5-3-8)13(17)10-6-11(15(19)20)14(18)12(16)7-10/h2-7,16,18H,1H3

                

                

                

                    
                    

                        
Molecular Formula

                        
C14H11NO5

                    

                    
                    

                        
HBD / HBA

                        
2 / 5

                    

                    
                    

                        
Вращаемые Связи

                        
2

                    

                    
                    
                    

                        
Тяжёлые Атомы

                        
20

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Часто задаваемые вопросы

                

                    
                    

                        
                        

                            
This medication is used as an add-on treatment to levodopa/carbidopa therapy in Parkinson's disease patients who are experiencing fluctuations in symptom control ("wearing off" episodes). It works by blocking an enzyme called COMT, which breaks down levodopa, allowing more of it to reach the brain. Due to the risk of serious liver damage, it requires regular liver function monitoring and is only used when other options have not worked.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Tolcapone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1324.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 4659569.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Медицинский отказ от ответственности

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.